PTGS2 and ovarian cancer: Because the elevated expression of COX-1 instead of COX-2 was detected in 22 ovarian cancer tissues compared with that in normal cases [56], and SC-560 (a COX-1 inhibitor) can suppress the production of PGE2 in three ovarian cancer cell lines while NS-398 and rofecoxib (COX-2 inhibitors) can not [56].